Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508926 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL21267453 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL22860576 | 0.96 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL29508837 | 0.96 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL4288197 | 0.90 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL14484056 | 0.86 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL22860586 | 0.83 | HTR6 (0.43) | KMT2AMEN1PIK3CDCSF1RCDK4 | |
| SCHEMBL10036371 | 0.83 | MAPT (0.55) | ALDH1A1LMNAMAPTGFERMAP4K4 | |
| SCHEMBL22852518 | 0.82 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL3572425 | 0.81 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTMAPK1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | ALDH1A1 2534/4885LMNA 2478/4885MAPT 3390/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885MAPT 3156/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885MAPT 3156/4885 |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885MAPT 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.